ArticleLeukemia2022
Genomic profiling identifies distinct genetic subtypes in extra-nodal natural killer/T-cell lymphoma.
Article in Leukemia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 42 citations in OpenAlex.
- Role of PRDM1 in natural killer cells.Molecular biology reports · 2026Review
- CNS involvement by EBV-positive extranodal T-cell lymphoma harboring STAT3 Y640F mutation following allogeneic hematopoietic stem cell transplantation: A case report.Radiology case reports · 2026Article
- Article
- Focus on extranodal NK/T cell lymphomas.Leukemia · 2026Article
- Article
- Epstein-Barr Virus-Associated T/NK-Cell Neoplasms.Journal of medical virology · 2026Review
- Peripheral blood immune profiling reveals key signatures in newly diagnosed NK/T cell lymphoma patients.Theranostics · 2026Article
- Radiotherapy alone versus combined therapy in stage I natural killer/T-cell lymphoma: impact of local invasion on treatment outcomes.Clinical and experimental medicine · 2025Article
- Extranodal NK/T-cell lymphoma: an update of the molecular characterization of the tumor and microenvironment, and its clinical implications.The Lancet regional health. Western Pacific · 2025Review
- Incidence, Prognostic Factors, and Treatment Impact on Survival in Natural Killer/T-Cell Lymphoma: Population-Based Study in the United States.JMIR formative research · 2025Article
- Advances in peripheral T cell lymphomas: pathogenesis, genetic landscapes and emerging therapeutic targets.Histopathology · 2025Review
- Review
- Analysis of mutation profiles in extranodal NK/T-cell lymphoma: clinical and prognostic correlations.Annals of hematology · 2024Article
- Full-spectral genome analysis of natural killer/T cell lymphoma highlights impacts of genome instability in driving its progression.Genome medicine · 2024Article
- Article
- EBV-Related Lymphoproliferative Diseases: A Review in Light of New Classifications.Mediterranean journal of hematology and infectious diseases · 2024Review
- Optimizing the combination of chemotherapeutic drugs along with radiotherapy for extranodal NK/T-cell lymphoma.Therapeutic advances in medical oncology · 2024Article
- Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders.Current hematologic malignancy reports · 2023Review
- Biology and genetics of extranodal mature T-cell and NKcell lymphomas and lymphoproliferative disorders.Haematologica · 2023Review
- Clinical and prognostic role of sarcopenia based on masticatory muscle index on MR images in patients with extranodal natural killer/T cell lymphoma, nasal type.Annals of hematology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 11 institutions in 5 countries.
Funding
Abstract
Extra-nodal NK/T-cell lymphoma, nasal type (ENKTCL) is a highly aggressive Epstein-Barr virus associated lymphoma, typically presenting in the nasal and paranasal areas. We assembled a large series of ENKTCL (n = 209) for comprehensive genomic analysis and correlative clinical study. The International Lymphoma Prognostic Index (IPI), site of disease, stage, lymphadenopathy, and hepatomegaly were associated with overall survival. Genetic analysis revealed frequent oncogenic activation of the JAK/STAT3 pathway and alterations in tumor suppressor genes (TSGs) and genes associated with epigenomic regulation. Integrated genomic analysis including recurrent mutations and genomic copy number alterations using consensus clustering identified seven distinct genetic clusters that were associated with different clinical outcomes, thus constituting previously unrecognized risk groups. The genetic profiles of ENTKCLs from Asian and Hispanic ethnic groups showed striking similarity, indicating shared pathogenetic mechanism and tumor evolution. Interestingly, we discovered a novel functional cooperation between activating STAT3 mutations and loss of the TSG, PRDM1, in promoting NK-cell growth and survival. This study provides a genetic roadmap for further analysis and facilitates investigation of actionable therapeutic opportunities in this aggressive lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.